Precision Neuroscience Raises $250 Million in Series D Funding
Precision Neuroscience, a company dedicated to leveraging brain-computer interface (BCI) technology to unlock the full potential of the brain, has successfully raised $250 million in its Series D funding round. The financing was led by Pershing Square Inc. and the Ackman Oxman Institute, with participation from notable investors such as Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital.
Investment Details
This latest funding round, concluded on September 24, 2026, boosts Precision Neuroscience’s total capital raised to $430 million. The New York-based company has demonstrated significant progress in the BCI field, having conducted over 100 patient procedures across 18 major medical institutions.
Leadership Insight
Michael Mager, Co-Founder and CEO of Precision Neuroscience, highlighted the importance of this funding in expanding the company's capabilities within the emerging BCI sector. He noted that the next phase of development in this field will not rely solely on technological advances.
Strategic Use of Funds
While specific use cases for the newly acquired funds were not elaborated, the capital is expected to support the company's ongoing research and development efforts. Precision Neuroscience is known for its FDA-cleared Layer 7™ cortical interface and its commercial partnership with Medtronic. Additionally, the company operates a MEMS manufacturing facility in Texas, which may benefit from this financial injection.
Market Position
By securing this substantial investment, Precision Neuroscience continues to solidify its position as a leader in the BCI space. The diverse group of investors reflects a broad confidence in the potential of BCI technologies to transform healthcare and technology sectors.